UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 3.304

Sortiert nach

Neutral super-oxidised solutions are effective in killing P. aeruginosa biofilms

Biofouling (Chur, Switzerland), 2009-01, Vol.25 (1), p.45-54

2009

Volltextzugriff (PDF)

Testing Biological Hypotheses with Embodied Robots: Adaptations, Accidents, and By-Products in the Evolution of Vertebrates

Frontiers in robotics and AI, 2014-01, Vol.1

2014

Volltextzugriff (PDF)

Temporal trends in respiratory care and bronchopulmonary dysplasia in very preterm infants over a 10-year period in Spain

Archives of disease in childhood. Fetal and neonatal edition, 2022-03, Vol.107 (2), p.143

2022

Volltextzugriff (PDF)

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

The oncologist (Dayton, Ohio), 2022-06, Vol.27 (6), p.453-461

2022

Volltextzugriff (PDF)

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2616-2616

2021

Volltextzugriff (PDF)

Immunogenicity and disease control induced by a multineoantigen vaccine (ADXS-503) in patients with metastatic non–small cell lung cancer who have progressed on pembrolizumab

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9042-9042

2022

Volltextzugriff (PDF)

A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9038-9038

2022

Volltextzugriff (PDF)

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5115-TPS5115

2022

Volltextzugriff (PDF)

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21682-e21682

2020

Volltextzugriff (PDF)

KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.126-126

2020

Volltextzugriff (PDF)

Abstract 1671: Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1671-1671

2021

Volltextzugriff (PDF)

Abstract CT007: Safety and immunogenicity of a personalized neoantigen- Listeria vaccine in cancer patients

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT007-CT007

2019

Volltextzugriff (PDF)

One-oligonucleotide method for constructing vectors for RNA interference

Acta pharmacologica Sinica, 2005-12, Vol.26 (12), p.1467-1473

2005

Volltextzugriff (PDF)

Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7005-7005

2016

Volltextzugriff (PDF)

Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines

Endocrine, 2007-10, Vol.32 (2), p.129-135

2007

Volltextzugriff (PDF)

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4514-4514

2013

Volltextzugriff (PDF)

A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS3106-TPS3106

2013

Volltextzugriff (PDF)

Gene therapy for cancer using tumour-specific prodrug activation

Gene therapy, 1994-05, Vol.1 (3), p.170

1994

Volltextzugriff (PDF)

One‐oligonucleotide method for constructing vectors for RNA interference1

Acta pharmacologica Sinica, 2005-12, Vol.26 (12), p.1467-1473

2005

Volltextzugriff (PDF)

Effects of pH-neutral, super-oxidised solution on human dermal fibroblasts in vitro

International wound journal, 2007-09, Vol.4 (3), p.241-250

2007

Volltextzugriff (PDF)

Activation of a Ca2+-permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line

The Journal of physiology, 1999-05, Vol.517 (1), p.95-107

1999

Volltextzugriff (PDF)

Identification of K-ras mutations in pancreatic juice

Annals of internal medicine, 1996-06, Vol.124 (11), p.1014

1996

Volltextzugriff (PDF)

Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study

Influenza and other respiratory viruses, 2017-03, Vol.11 (2), p.157-164

2017

Volltextzugriff (PDF)

Activation of a Ca 2+ ‐permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line

The Journal of physiology, 1999-05, Vol.517 (1), p.95-107

1999

Volltextzugriff (PDF)

Predischarge morbidities in extremely and very low-birth-weight infants in Spanish neonatal units

American journal of perinatology, 2009-05, Vol.26 (5), p.335

2009

Volltextzugriff (PDF)

1 – 25 von 3.304

Suche als RSS-Feed

Aktive Filter

ThemaBiological And Medical Sciences

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(3.057)

Publikationsform

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(55)
Blood
(46)
Plos One
(32)
Dyna
(27)
Transplantation And Cellular Therapy
(27)
Acta Biológica Colombiana
(25)
Revista De Neurologiá
(22)
International Journal Of Molecular Sciences
(20)
Scientific Reports
(20)
Cirugia Española
(19)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Neutral super-oxidised solutions are effective in killing P. aeruginosa biofilms

Testing Biological Hypotheses with Embodied Robots: Adaptations, Accidents, and By-Products in the Evolution of Vertebrates

Temporal trends in respiratory care and bronchopulmonary dysplasia in very preterm infants over a 10-year period in Spain

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Immunogenicity and disease control induced by a multineoantigen vaccine (ADXS-503) in patients with metastatic non–small cell lung cancer who have progressed on pembrolizumab

A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel

Abstract 1671: Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets

Abstract CT007: Safety and immunogenicity of a personalized neoantigen- Listeria vaccine in cancer patients

One-oligonucleotide method for constructing vectors for RNA interference

Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR)

Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up

A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors

Gene therapy for cancer using tumour-specific prodrug activation

One‐oligonucleotide method for constructing vectors for RNA interference1

Effects of pH-neutral, super-oxidised solution on human dermal fibroblasts in vitro

Activation of a Ca2+-permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line

Identification of K-ras mutations in pancreatic juice

Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study

Activation of a Ca 2+ ‐permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line

Predischarge morbidities in extremely and very low-birth-weight infants in Spanish neonatal units

Aktive Filter

Suchergebnisse filtern